https://www.biospace.com/subcutaneously-administered-pd-l1-antibody-asc22-envafolimab-is-safe-and-well-tolerated-in-phase-iia-hbv-study
Ascletis Pharma Inc. (HKEX:1672) announces today that Phase IIa data demonstrated that ASC22 (Envafolimab) is safe and well tolerated in chronic hepatitis B...
subcutaneouslypdantibodyenvafolimabsafe
https://www.pharmaceutical-technology.com/data-insights/envafolimab-alphamab-oncology-head-and-neck-cancer-likelihood-of-approval/
Envafolimab is under clinical development by Alphamab Oncology and currently in Phase I for Head And Neck Cancer.
neck cancerenvafolimaboncologyheadlikelihood
https://www.pharmaceutical-technology.com/data-insights/envafolimab-alphamab-oncology-cutaneous-squamous-cell-carcinoma-cscc-likelihood-of-approval/
Envafolimab is under clinical development by Alphamab Oncology and currently in Phase II for Cutaneous Squamous Cell Carcinoma (cSCC).
squamous cell carcinomaenvafolimaboncologycutaneouscscc
https://www.pharmaceutical-technology.com/data-insights/envafolimab-alphamab-oncology-ovarian-cancer-likelihood-of-approval/
Envafolimab is under clinical development by Alphamab Oncology and currently in Phase II for Ovarian Cancer.
ovarian cancerenvafolimaboncologylikelihoodapproval